Navigation Links
New drug strategy attacks resistant leukemia and lymphoma
Date:5/29/2012

BOSTON--Scientists at the Dana-Farber/Children's Hospital Cancer Center have developed an anti-cancer peptide that overcomes the stubborn resistance to chemotherapy and radiation often encountered in certain blood cancers when the disease recurs following initial treatment.

The strategy could pave the way for much needed new therapies to treat relapsed and refractory blood cancers, which are difficult to cure because their cells deploy strong protein "deflector shields" to neutralize the cell death signals that chemotherapy agents used against them initially, say the researchers.

The prototype compound, called a "stapled BIM BH3 peptide," is designed to disable the cancer's defenses by hitting a family of protein targets that regulate cell death.

In proof-of-concept studies in mice with transplanted, drug-resistant leukemia tumors, the compound alone suppressed cancer growth, and when paired with other drugs, showed synergistic anti-cancer activity, say researchers led by Loren Walensky, MD, PhD, of Dana-Farber/Children's Hospital Cancer Center.

Their paper has been posted online by the Journal of Clinical Investigation and will appear in the journal's June issue. Walensky is the senior author and James LaBelle, MD, PhD, is the first author.

A cell's "fate" when and whether it lives or dies depends on a tug-of-war between pro-death and anti-death forces within the cell that serve as a check-and-balance system to maintain orderly growth. The system is regulated by the BCL-2 family of proteins, which contains both pro-death and pro-survival members.

When cells are no longer needed or are damaged beyond repair, the body activates pro-death BCL-2 proteins to shut down mitochondria the power plants of the cell resulting in an orchestrated cellular destruction known as apoptosis, or programmed cell death.

Many cell-killing cancer treatments work by triggering these "executioner proteins" t
'/>"/>

Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-632-5357
Dana-Farber Cancer Institute
Source:Eurekalert  

Page: 1 2 3

Related medicine news :

1. Strategy discovered to activate genes that suppress tumors and inhibit cancer
2. Discovery suggests new combination therapy strategy for basal-like breast cancers
3. White House Drug Policy Shifts Strategy
4. Scripps research scientists illuminate cancer cells survival strategy
5. Scientists report first step in strategy for cell replacement therapy in Parkinsons disease
6. Novel strategy stymies SARS et al.
7. UCSF tapped for US National AIDS Strategy initiative
8. Federal government releases environmental, health, and safety research strategy for nanotechnology
9. Miriam Hospital researchers pilot new acute hepatitis C screening strategy for HIV-infected patients
10. Strategy for improving health care for uninsured, low-income, and minorities in the US
11. New strategy likely to speed drug development for rare cancers
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New drug strategy attacks resistant leukemia and lymphoma
(Date:10/30/2014)... 30, 2014 Victory Healthcare, a ... 2014 third quarter infection rates and patient satisfaction ... rates of only two percent or less, and ... exceeding 98 percent. , “We are delighted with ... rising satisfaction scores,” said Robert Helms, chairman and ...
(Date:10/30/2014)... who used stem cells to create miniature human stomachs ... new way to learn more about the development and ... pluripotent stem cells -- which can become any type ... functional miniature stomachs, to study infection by H. ... stomach cancer. The miniature stomachs offer many research ...
(Date:10/30/2014)... Oct. 29, 2014 (HealthDay News) -- Many U.S. ... campus, even though tanning increases the risk for ... among young adults, particularly white women, so colleges ... health, the researchers said. "Public health efforts ... population awareness of the harms that indoor tanning ...
(Date:10/30/2014)... -- A new vaccine that could help prevent some ... the U.S. Food and Drug Administration on Wednesday. ... of 10 and 25 from invasive meningococcal disease caused ... The bacteria can infect the bloodstream (sepsis) and the ... is a leading cause of bacterial meningitis, and infection ...
(Date:10/29/2014)... development of minimally and even non-invasive technologies is increasing ... instance, to carry out a range of operative procedures ... leaving only tiny scars as a result. Similar opportunities ... agents to patients – instead of using injections or ... possible to supply them via a plaster which continuously, ...
Breaking Medicine News(10 mins):Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 2Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 3Health News:Many U.S. Colleges Have Indoor Tanning Salons On, Near Campus: Study 2Health News:FDA Approves New Vaccine to Protect Against Meningitis 2Health News:Gentle caffeine boost for premature babies 2
... . , The PhD, defended by Ana ... Country, proposes a series of recommendations that contribute to ... treat terminal cancer patients. , Autonomy is the capacity ... knowledge about the causes of the illness, sufficient information ...
... Shared Health, Inc.,provider of secure health information ... Tennessee to provide its electronic health record,solutions ... health information,network called the Tennessee Information Network ... partnership with the State of Tennessee began ...
... The Providence Service,Corporation (Nasdaq: PRSC ) today announced ... fourth quarter and year ended December 31, 2007,on Wednesday, ... will hold a conference call at 11:00 a.m. EDT ... March 13, 2008 to discuss its,financial results and corporate ...
... Bowl champ O.J. Brigance,who recently confirmed a diagnosis ... The Robert Packard Center for ALS Research at ... the Center to fund,research to find a cure ... (Photo: http://www.newscom.com/cgi-bin/prnh/20080303/NEM042 ), The ...
... Faculty of 1000 Medicine, researchers look at the way ... used by physicians in Quebec. , The authors ... that general practitioners diagnosed 79% of the 10,001 rheumatoid ... a rheumatologist. Half of these patients were seen in ...
... study has found that elevated liver enzymes discovered ... future mortality. The findings are in the March ... Wiley & Sons on behalf of the American ... The article is also available online at Wiley ...
Cached Medicine News:Health News:Factors that enhance autonomy of cancer patients 2Health News:Factors that enhance autonomy of cancer patients 3Health News:Shared Health Partners With State of Tennessee to Provide Electronic Health Information for Statewide Health Information Network 2Health News:Providence Service Corporation to Report Fourth Quarter 2007 Results on Wednesday, March 12th After the Market Closes 2Health News:Providence Service Corporation to Report Fourth Quarter 2007 Results on Wednesday, March 12th After the Market Closes 3Health News:O.J. Brigance Named Honorary Chair of May 3 Race to Cure ALS, Confirms His Diagnosis by The Robert Packard Center for ALS Research at Johns Hopkins 2Health News:Elevated liver enzymes associated with higher future mortality 2
(Date:10/30/2014)... LOS ANGELES , Oct. 29, 2014 /PRNewswire/ ... pharmaceutical company devoted to bringing new products to ... 2015. ViaDerma has developed an innovative, ... for rapid mass transfer of pharmaceutical active ingredients ... to provide immediate localized therapy. The transdermal delivery ...
(Date:10/30/2014)... Oct. 30, 2014 Today Eli Lilly and ... its long-standing technology transfer program to increase the global ... 2003, the effort included Lilly donating manufacturing technology and ... China , India , ... Africa – all MDR-TB ,hot spots., It ...
(Date:10/27/2014)... , Oct. 27, 2014  Demonstrations by ... devices are being featured this week in ... Scientific Assembly where more than 7,000 emergency physicians ... and participating in educational courses. These ... drop of true-to-life emergency department environments, including three ...
Breaking Medicine Technology:ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3Lilly Shares Insights from Decade-Long Technology Transfer Experience 2Lilly Shares Insights from Decade-Long Technology Transfer Experience 3Lilly Shares Insights from Decade-Long Technology Transfer Experience 4Emergency Medicine of the Future Demonstrated at ACEP14 2Emergency Medicine of the Future Demonstrated at ACEP14 3Emergency Medicine of the Future Demonstrated at ACEP14 4Emergency Medicine of the Future Demonstrated at ACEP14 5Emergency Medicine of the Future Demonstrated at ACEP14 6Emergency Medicine of the Future Demonstrated at ACEP14 7Emergency Medicine of the Future Demonstrated at ACEP14 8Emergency Medicine of the Future Demonstrated at ACEP14 9Emergency Medicine of the Future Demonstrated at ACEP14 10Emergency Medicine of the Future Demonstrated at ACEP14 11Emergency Medicine of the Future Demonstrated at ACEP14 12Emergency Medicine of the Future Demonstrated at ACEP14 13Emergency Medicine of the Future Demonstrated at ACEP14 14Emergency Medicine of the Future Demonstrated at ACEP14 15
Preference Toric quarterly planned replacement lenses are durable, easy to handle and virtually maintenance free. Meeting the needs of those suffering from astigmatism, these soft contact lenses are ...
... fit for all astigmatic patients. Ideal ... who require excellent visual acuity and ... of disposable lenses; astigmatic spectacle wearers ... lenses; and spherically masked astigmatic patients ...
C 2.3K with lightweight headband: the practical alternative for spectacle-wearers. Delivered in protective designer case....
... Vitrasert implant is a device ... with Aids-related Cytomegalovirus (CMV) Retinitis. This ... CMV when compared with conventional intravenous ... embedded in a polymer-based system that ...
Medicine Products: